Optimal Managements of Elderly Patients with Glioblastoma

Overview

Journal Jpn J Clin Oncol

Publisher Oxford University Press

Specialty Oncology

Date 2022 May 13

PMID 35552425

Authors

Yoshiki Arakawa

Yohei Mineharu

Megumi Uto

Takashi Mizowaki

Affiliations

Soon will be listed here.

Abstract

Optimizing the management of elderly patients with glioblastoma is an ongoing task in neuro-oncology. The number of patients with this tumor type is gradually increasing with the aging of the population. Although available data and practice recommendations remain limited, the current strategy is maximal safe surgical resection followed by radiotherapy in combination with temozolomide. However, survival is significantly worse than that in the younger population. Surgical resection provides survival benefit in patients with good performance status. Hypofractionated radiotherapy decreases toxicities while maintaining therapeutic efficacy, thus improving treatment adherence and subsequently leading to better quality of life. The intensity of these treatments should be balanced with patient-specific factors and consideration of quality of life. This review discusses the current optimal management in terms of efficacy and safety, as well as future perspectives.

Citing Articles

The Karnofsky Performance Status at Discharge Is a Prognostic Indicator of Life Expectancy in Patients With Glioblastoma.

Sasaki S, Tsukamoto S, Ishida Y, Kobayashi Y, Inagaki Y, Mano T Cureus. 2024; 16(8):e66226.

PMID: 39238708 PMC: 11376000. DOI: 10.7759/cureus.66226.

Diagnostic and Prognostic Value of Circulating DNA Fragments in Glioblastoma Multiforme Patients.

Jarmuzek P, Wawrzyniak-Gramacka E, Morawin B, Tylutka A, Zembron-Lacny A Int J Mol Sci. 2024; 25(8).

PMID: 38673808 PMC: 11049819. DOI: 10.3390/ijms25084221.

References

Chandra A, Lopez-Rivera V, Dono A, Brandel M, Lewis C, OConnor K . Comparative Analysis of Survival Outcomes and Prognostic Factors of Supratentorial versus Cerebellar Glioblastoma in the Elderly: Does Location Really Matter?. World Neurosurg. 2020; 146:e755-e767. DOI: 10.1016/j.wneu.2020.11.003. View

. Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir (Tokyo). 2017; 57(Suppl 1):9-102. PMC: 6760096. DOI: 10.2176/nmc.sup.2017-0001. View

Lombardi G, Bergo E, Caccese M, Padovan M, Bellu L, Brunello A . Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients. Cancers (Basel). 2019; 11(10). PMC: 6826848. DOI: 10.3390/cancers11101509. View

Hirata E, Arakawa Y, Shirahata M, Yamaguchi M, Kishi Y, Okada T . Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 2009; 100(8):1451-9. PMC: 11158953. DOI: 10.1111/j.1349-7006.2009.01189.x. View

Brandes A, Vastola F, Basso U, Berti F, Pinna G, Rotilio A . A prospective study on glioblastoma in the elderly. Cancer. 2003; 97(3):657-62. DOI: 10.1002/cncr.11097. View

Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H . Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7(5):392-401. DOI: 10.1016/S1470-2045(06)70665-9. View

Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D . International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015; 33(35):4145-50. DOI: 10.1200/JCO.2015.62.6606. View

Barazzuol L, Burnet N, Jena R, Jones B, Jefferies S, Kirkby N . A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects. J Theor Biol. 2009; 262(3):553-65. DOI: 10.1016/j.jtbi.2009.10.021. View

Qi X, Schultz C, Li X . An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor. Int J Radiat Oncol Biol Phys. 2006; 64(5):1570-80. DOI: 10.1016/j.ijrobp.2005.12.022. View

10.

Lutgendorf-Caucig C, Freyschlag C, Masel E, Marosi C . Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. Curr Oncol Rep. 2020; 22(9):93. PMC: 7351817. DOI: 10.1007/s11912-020-00951-6. View

11.

Salazar O, Rubin P, Feldstein M, Pizzutiello R . High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979; 5(10):1733-40. DOI: 10.1016/0360-3016(79)90554-6. View

12.

Haque W, Verma V, Butler E, Teh B . Patterns of Care and Outcomes of Hypofractionated Chemoradiation Versus Conventionally Fractionated Chemoradiation for Glioblastoma in the Elderly Population. Am J Clin Oncol. 2018; 41(2):167-172. DOI: 10.1097/COC.0000000000000417. View

13.

Chen B, Chen C, Zhang Y, Xu J . Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017. BMC Cancer. 2021; 21(1):54. PMC: 7802341. DOI: 10.1186/s12885-020-07778-1. View

14.

Bingham B, Patel C, Shinohara E, Attia A . Utilization of hypofractionated radiotherapy in treatment of glioblastoma multiforme in elderly patients not receiving adjuvant chemoradiotherapy: A National Cancer Database Analysis. J Neurooncol. 2017; 136(2):385-394. DOI: 10.1007/s11060-017-2665-8. View

15.

Bleehen N, Stenning S . A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991; 64(4):769-74. PMC: 1977696. DOI: 10.1038/bjc.1991.396. View

16.

Guedes de Castro D, Matiello J, Roa W, Ghosh S, Kepka L, Kumar N . Survival Outcomes With Short-Course Radiation Therapy in Elderly Patients With Glioblastoma: Data From a Randomized Phase 3 Trial. Int J Radiat Oncol Biol Phys. 2017; 98(4):931-938. DOI: 10.1016/j.ijrobp.2017.03.037. View

17.

Perlow H, Yaney A, Yang M, Klamer B, Matsui J, Raval R . Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. J Neurooncol. 2022; 156(2):399-406. DOI: 10.1007/s11060-021-03925-1. View

18.

da Cunha M, Esmeraldo A, Henriques L, Santos Jr M, Medeiros R, Botelho R . Elderly patients with glioblastoma: the impact of surgical resection extent on survival. Rev Assoc Med Bras (1992). 2019; 65(7):937-945. DOI: 10.1590/1806-9282.65.7.937. View

19.

Brandes A, Franceschi E, Tosoni A, Benevento F, Scopece L, Mazzocchi V . Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer. 2009; 115(15):3512-8. DOI: 10.1002/cncr.24406. View

20.

Ohno M, Miyakita Y, Takahashi M, Igaki H, Matsushita Y, Ichimura K . Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Radiat Oncol. 2019; 14(1):200. PMC: 6852964. DOI: 10.1186/s13014-019-1389-7. View